{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:43:34Z","timestamp":1791996214067,"version":"4.4.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>This study aimed to characterize incidences of CMV reactivations within one year post-allo-SCT and identify risk factors for CMV second reactivation episode in population with high seropositivity where first CMV reactivation episode deemed to be high.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective cohort study analyzed data from 359 allo-SCT patients aged 14 and older admitted to a tertiary academic hospital. Data on demographic and clinical factors, CMV serostatus, conditioning regimens, graft-versus-host disease prophylaxis, engraftment time, and CMV reactivations were collected.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>First and second CMV reactivations occurred in 88.9% and 18.4% of post-allo-SCT patients respectively. Patients were stratified into two groups based on primary disease necessitating allo-SCT, patients with malignant (Group 1) and non-malignant (Group 2) hematological disease. Factors associated with the second reactivation included cord blood as a stem cell source, human leukocyte antigen mismatch, acute graft-versus-host disease, and hematological malignancies. Patients with non-malignant hematological disease displayed better outcomes, including a higher rate of spontaneous clearance of first CMV reactivation (70% versus 49.4%) and lower rates of second CMV reactivation (9.6% versus 31%) than those with malignant hematological disease. The one-year overall survival rate was 87.7% (95.5% in non-malignant hematological disease and 78.13% in malignant hematological disease).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our findings are concordant with previous local study in regard to high rate of first CMV reactivation post-allo-SCT. It appears that patients with nonmalignant hematological disease had better outcomes, such as lower second CMV reactivation and higher survival rates compared to patients with malignant hematological disease. Further investigation is needed to identify other factors affecting recurrent CMV reactivations in allo-SCT in patients with malignant hematological disease.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12985-024-02421-y","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T05:24:53Z","timestamp":1719897893000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Characterization of recurrent cytomegalovirus reactivations post allogenic stem cell transplantation in a population with high seropositivity"],"prefix":"10.1186","volume":"21","author":[{"given":"Hajar Y.","family":"AlQahtani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"AlSuhebany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuroug A.","family":"Alowais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashayer","family":"AlShehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Althemery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirah","family":"Alghanim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hessa","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lama","family":"Alkhathran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majd","family":"Alyaqub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Alsulimani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"AlHarbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hind","family":"Alhatmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Almansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulellah","family":"Almohaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Bosaeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"issue":"20","key":"2421_CR1","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","volume":"127","author":"P Teira","year":"2016","unstructured":"Teira P, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016;127(20):2427\u201338.","journal-title":"Blood"},{"issue":"3","key":"2421_CR2","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","volume":"3","author":"ML Green","year":"2016","unstructured":"Green ML, et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol. 2016;3(3):e119\u201327.","journal-title":"Lancet Haematol"},{"issue":"3","key":"2421_CR3","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.blre.2017.01.002","volume":"31","author":"ST Chan","year":"2017","unstructured":"Chan ST, Logan AC. The clinical impact of cytomegalovirus infection following allogeneic hematopoietic cell transplantation: Why the quest for meaningful prophylaxis still matters. Blood Rev. 2017;31(3):173\u201383.","journal-title":"Blood Rev"},{"issue":"3","key":"2421_CR4","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1086\/338624","volume":"185","author":"WG Nichols","year":"2002","unstructured":"Nichols WG, et al. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis. 2002;185(3):273\u201382.","journal-title":"J Infect Dis"},{"issue":"3","key":"2421_CR5","doi-asserted-by":"publisher","first-page":"e2034","DOI":"10.1002\/rmv.2034","volume":"29","author":"M Zuhair","year":"2019","unstructured":"Zuhair M, et al. Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis. Rev Med Virol. 2019;29(3):e2034.","journal-title":"Rev Med Virol"},{"issue":"3","key":"2421_CR6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40506-021-00253-w","volume":"13","author":"N Jakharia","year":"2021","unstructured":"Jakharia N, Howard D, Riedel DJ. CMV infection in hematopoietic stem cell transplantation: prevention and treatment strategies. Curr Treat Options Infect Dis. 2021;13(3):123\u201340.","journal-title":"Curr Treat Options Infect Dis"},{"issue":"7","key":"2421_CR7","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1007\/s00277-022-04841-8","volume":"101","author":"M Vallejo","year":"2022","unstructured":"Vallejo M, et al. Risk prediction of CMV reactivation after allogeneic stem cell transplantation using five non-HLA immunogenetic polymorphisms. Ann Hematol. 2022;101(7):1567\u201376.","journal-title":"Ann Hematol"},{"issue":"3","key":"2421_CR8","doi-asserted-by":"publisher","first-page":"169 e1","DOI":"10.1016\/j.jtct.2021.12.014","volume":"28","author":"J Mariotti","year":"2022","unstructured":"Mariotti J, et al. Risk factors for early cytomegalovirus reactivation and impact of early cytomegalovirus reactivation on clinical outcomes after T cell-replete haploidentical transplantation with post-transplantation cyclophosphamide. Transplant Cell Ther. 2022;28(3):169 e1-169 e9.","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"2421_CR9","doi-asserted-by":"publisher","first-page":"515","DOI":"10.6061\/clinics\/2015(07)09","volume":"70","author":"LS Azevedo","year":"2015","unstructured":"Azevedo LS, et al. Cytomegalovirus infection in transplant recipients. Clinics (Sao Paulo). 2015;70(7):515\u201323.","journal-title":"Clinics (Sao Paulo)"},{"issue":"3","key":"2421_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1399-3062.2011.00689.x","volume":"14","author":"JS Chawla","year":"2012","unstructured":"Chawla JS, et al. Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04\u20130274) and review of the literature. Transpl Infect Dis. 2012;14(3):259\u201367.","journal-title":"Transpl Infect Dis"},{"issue":"4","key":"2421_CR11","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1182\/blood.V99.4.1159","volume":"99","author":"P Reusser","year":"2002","unstructured":"Reusser P, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood. 2002;99(4):1159\u201364.","journal-title":"Blood"},{"issue":"9","key":"2421_CR12","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.jtct.2021.05.001","volume":"27","author":"M Hakki","year":"2021","unstructured":"Hakki M, et al. American Society for transplantation and cellular therapy series: #3-Prevention of cytomegalovirus infection and disease after hematopoietic cell transplantation. Transplant Cell Ther. 2021;27(9):707\u201319.","journal-title":"Transplant Cell Ther"},{"issue":"25","key":"2421_CR13","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","volume":"377","author":"FM Marty","year":"2017","unstructured":"Marty FM, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377(25):2433\u201344.","journal-title":"N Engl J Med"},{"issue":"3","key":"2421_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.retram.2020.04.005","volume":"68","author":"M Damlaj","year":"2020","unstructured":"Damlaj M, et al. Optimal pre-emptive cytomegalovirus therapy threshold in a patient population with high prevalence of seropositive status. Curr Res Transl Med. 2020;68(3):131\u20137.","journal-title":"Curr Res Transl Med"},{"key":"2421_CR15","doi-asserted-by":"crossref","unstructured":"Abbott Real Time CMV m2000rt assay for CMV amplification A.M. Inc, Editor. 2017, Abbott Laboratories Des Plaines. p. 1\u201315.","DOI":"10.1016\/S1773-035X(17)30354-4"},{"issue":"1","key":"2421_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/cid\/ciw668","volume":"64","author":"P Ljungman","year":"2017","unstructured":"Ljungman P, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017;64(1):87\u201391.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"2421_CR17","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628\u201333.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2421_CR18","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1182\/blood-2014-02-514778","volume":"124","author":"B Gyurkocza","year":"2014","unstructured":"Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood. 2014;124(3):344\u201353.","journal-title":"Blood"},{"issue":"3","key":"2421_CR19","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","volume":"15","author":"S Giralt","year":"2009","unstructured":"Giralt S, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15(3):367\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2421_CR20","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3324\/haematol.2019.229252","volume":"106","author":"E Wagner-Drouet","year":"2021","unstructured":"Wagner-Drouet E, et al. Standardized monitoring of cytomegalovirus-specific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantation. Haematologica. 2021;106(2):363\u201374.","journal-title":"Haematologica"},{"issue":"1","key":"2421_CR21","doi-asserted-by":"publisher","first-page":"82 e1","DOI":"10.1016\/j.bbmt.2020.10.001","volume":"27","author":"K Takenaka","year":"2021","unstructured":"Takenaka K, et al. Negative impact of cytomegalovirus reactivation on survival in adult patients with aplastic anemia after an allogeneic hematopoietic stem cell transplantation: a report from transplantation-related complication and adult aplastic anemia working groups of the Japan Society for hematopoietic cell transplantation. Transplant Cell Ther. 2021;27(1):82 e1-82 e8.","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"2421_CR22","first-page":"78","volume":"91","author":"P Ljungman","year":"2006","unstructured":"Ljungman P, et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica. 2006;91(1):78\u201383.","journal-title":"Haematologica"},{"issue":"1","key":"2421_CR23","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.hoc.2010.11.011","volume":"25","author":"P Ljungman","year":"2011","unstructured":"Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am. 2011;25(1):151\u201369.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"3","key":"2421_CR24","doi-asserted-by":"publisher","first-page":"e620","DOI":"10.1093\/cid\/ciaa1871","volume":"73","author":"Y Akahoshi","year":"2021","unstructured":"Akahoshi Y, et al. Effect of cytomegalovirus reactivation with or without acute graft-versus-host disease on the risk of nonrelapse mortality. Clin Infect Dis. 2021;73(3):e620\u20138.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"2421_CR25","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.bbmt.2010.03.020","volume":"16","author":"N Cantoni","year":"2010","unstructured":"Cantoni N, et al. Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16(9):1309\u201314.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2421_CR26","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/s41409-018-0369-0","volume":"54","author":"H Yokoyama","year":"2019","unstructured":"Yokoyama H, et al. Effects of HLA mismatch on cytomegalovirus reactivation in cord blood transplantation. Bone Marrow Transplant. 2019;54(7):1004\u201312.","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2421_CR27","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1182\/bloodadvances.2022009112","volume":"7","author":"M Ueda Oshima","year":"2023","unstructured":"Ueda Oshima M, et al. Impact of GVHD prophylaxis on CMV reactivation and disease after HLA-matched peripheral blood stem cell transplantation. Blood Adv. 2023;7(8):1394\u2013403.","journal-title":"Blood Adv"},{"issue":"10","key":"2421_CR28","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1016\/j.bbmt.2018.05.001","volume":"24","author":"M Suarez-Lledo","year":"2018","unstructured":"Suarez-Lledo M, et al. Deleterious effect of steroids on cytomegalovirus infection rate after allogeneic stem cell transplantation depends on pretransplant cytomegalovirus serostatus of donors and recipients. Biol Blood Marrow Transplant. 2018;24(10):2088\u201393.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2421_CR29","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.bbmt.2010.04.011","volume":"17","author":"D Pastore","year":"2011","unstructured":"Pastore D, et al. Recovery of CMV-specific CD8+ T cells and Tregs after allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(4):550\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2421_CR30","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1182\/blood.V97.5.1232","volume":"97","author":"K Cwynarski","year":"2001","unstructured":"Cwynarski K, et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood. 2001;97(5):1232\u201340.","journal-title":"Blood"},{"issue":"10","key":"2421_CR31","doi-asserted-by":"publisher","first-page":"3690","DOI":"10.1182\/blood-2002-05-1387","volume":"100","author":"E Ozdemir","year":"2002","unstructured":"Ozdemir E, et al. Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells. Blood. 2002;100(10):3690\u20137.","journal-title":"Blood"},{"issue":"11","key":"2421_CR32","doi-asserted-by":"publisher","first-page":"105340","DOI":"10.1016\/j.isci.2022.105340","volume":"25","author":"J Zhang","year":"2022","unstructured":"Zhang J, et al. The establishment of a cytomegalovirus -specific CD8(+) T-cell threshold by kinetic modeling for the prediction of post-hemopoietic stem cell transplant reactivation. iScience. 2022;25(11):105340.","journal-title":"iScience"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-024-02421-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-024-02421-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-024-02421-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T05:30:17Z","timestamp":1719898217000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-024-02421-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2421"],"URL":"https:\/\/doi.org\/10.1186\/s12985-024-02421-y","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,2]]},"assertion":[{"value":"16 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of King Abdullah International Medical Research Center (protocol number NRC22R\/011\/01). Due to the design of this study, informed consent from patients was not required. The research was conducted in accordance with the Declaration of Helsinki. The research team restricted the participants\u2019 information and maintained confidentiality throughout the study period by assigning serial numbers to each participant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing financial interests or personal relationships that may have influenced the work reported in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"149"}}